PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
By PVI, PeerView Institute for Medical Education
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Category: Science
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 4
Reviews: 0
Episodes: 214
Description
PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
| Episode | Date |
|---|---|
|
Surya P. Bhatt, MD, MSPH - Breaking New Ground in the Treatment of COPD: Exploring the Potential Use of Targeted Biologic Therapy in Patients With Evidence of Type 2 Inflammation
|
Nov 12, 2024 |
|
Patrick M. Moriarty, MD, FACP, FACC, FNLA, FESC - Changing the Future for Families With HoFH: Long-Term Benefits of Early Diagnosis and Treatment for Homozygous Familial Hypercholesterolemia
|
Nov 01, 2024 |
|
Julie L. Rosenthal, MD, FACC, Ronald Witteles, MD - TTRansforming the TTReatment of ATTR: A Guide to the Pathophysiology, Diagnosis, and Emerging Treatment Strategies for ATTR Amyloidosis
|
Nov 01, 2024 |
|
Pamela J. McShane, MD - Experts vs AI Challenge: Diagnosing and Managing Nontuberculous Mycobacterial Lung Disease
|
Nov 01, 2024 |
|
Ibiayi Dagogo-Jack, MD / Jay M. Lee, MD - Reinforcing Precision Tactics in Genomically Altered Resectable NSCLC: Collaborative Workflows and Personalized Solutions for Integration of Adjuvant EGFR- and ALK-Targeted Therapies
|
Oct 28, 2024 |
|
Jessica Donington, MD, Jonathan D. Spicer, MD, PhD, FRCSC - Integrating Immunotherapy in Resectable NSCLC: How to Modify Treatment Trajectories and Reorganize Multidisciplinary Care Pathways
|
Oct 28, 2024 |
|
Dave Singh - Breathing New Life Into Treatment Approaches for COPD: The Latest Insights Into the Role of Type 2 Inflammation and Targeted Biologic Therapy
|
Oct 22, 2024 |
|
Suresh S. Ramalingam, MD, FACP, FASCO - Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC
|
Oct 04, 2024 |
|
Taofeek K. Owonikoko, MD, PhD - Taking a BiTE Out of SCLC: Are You Ready for a New Wave of DLL3-Targeting T-Cell Engagers and Other Therapies?
|
Oct 04, 2024 |
|
Stephen V. Liu, MD - Updating the Lung Cancer Treatment Algorithms With Novel Antibody–Drug Conjugates: Are You Prepared for Change? State of the Science, Implications for Practice, and Future Prospects
|
Oct 02, 2024 |
|
Prof. Solange Peters, MD, PhD - Are We Closer to a Cure With Perioperative Immunotherapy in Resectable NSCLC? Latest Evidence, Current Conclusions, and Ongoing Questions in Clinical Care
|
Oct 02, 2024 |
|
Roy S. Herbst, MD, PhD - Elevating Care in Resectable Stage I-III NSCLC: Targeted Therapy and Immunotherapy at the Forefront of Multimodal Treatment Strategies
|
Oct 02, 2024 |
|
Natasha B. Leighl, MD, MMSc, FRCPC, FASCO - Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC: A Practical Framework for Optimal Biomarker Testing, Treatment Selection and Sequencing, and Adverse Event Management
|
Oct 02, 2024 |
|
Marc S. Sabatine, MD, MPH - Emerging Options for Targeting PCSK9 in Hypercholesterolemia Management: Visualizing New Routes to Individualized Care
|
Sep 23, 2024 |
|
P. Barton Duell, MD - Lipid Management Beyond Statins: Early Screening, Prompt Intervention, and Timely Intensification With PCSK9-Targeted Therapies
|
Aug 20, 2024 |
|
Praveen Akuthota, MD - Recognizing the Burden of Patients Living With EGPA: An Exploration of Best Practices in Diagnosis and Treatment in the Context of a Multidisciplinary Approach
|
Jul 30, 2024 |
|
Ticiana Leal, MD - Achieving Optimal SCLC Care With Established and Innovative Therapies: Latest Evidence, Key Ongoing Trials, and Practical Considerations for Real-World Practice
|
Jul 26, 2024 |
|
Stephen V. Liu, MD - Decoding Biomarker Testing and Targeted Therapy in NSCLC: The Complete Guide for 2024
|
Jul 16, 2024 |
|
Geoffrey L. Chupp, MD / Autumn Burnette, MD, FACAAI - Leveraging the Power of Targeted Biologic Therapy in Severe Asthma: Do You Know How and For Whom?
|
Jul 04, 2024 |
|
Sandip Patel, MD - Illuminating the Path With Immunotherapy for Metastatic, Locally Advanced, and Early-Stage NSCLC: A Guide to Patient Assessment, Treatment Selection, and Multidisciplinary Collaboration Across the Disease Continuum
|
Jul 03, 2024 |
|
Peter Voorhees, MD - Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms
|
Jul 03, 2024 |
|
Kun "Kevin" Xiang, MD, PhD - Anticoagulation Therapy in NVAF: A Quality Improvement Initiative
|
Jun 19, 2024 |
|
William Anderson, MD - Improving Outcomes for Pediatric Patients With Uncontrolled Moderate-to-Severe Asthma Using a Collaborative Approach: Recognition, Referral, and Management in the Era of Targeted Treatment Options
|
Jun 19, 2024 |
|
Doreen J. Addrizzo-Harris, MD / Cedric "Jamie" Rutland, MD - Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understanding Disease Burden, Diagnosing Early, and Looking Toward New Management Options
|
Jun 11, 2024 |
|
Brett Elicker, MD / David E. Griffith, MD, ATSF, ACCP, OFRSM - Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging
|
Jun 11, 2024 |
|
Jessica Donington, MD - Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches
|
Jun 03, 2024 |
|
Marianne Davies, DNP, ACNP, AOCNP, FAAN / Beth Sandy, MSN, CRNP, FAPO - Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care
|
May 20, 2024 |
|
Milind Desai, MD, MBA, FACC, FAHA, FESC, Andrew Willeford, PharmD, PhD, BCCP - Adapting Managed Care Strategies in the Era of Precision Medicine for Hypertrophic Cardiomyopathy
|
May 10, 2024 |
|
Lecia V. Sequist, MD, MPH - Screening and Early Intervention as the Keys to Success in Lung Cancer: A Practical Approach to Implementing Lung Cancer Screening for High-Risk Individuals
|
May 06, 2024 |
|
A. Michael Lincoff, MD - Exploring the Evidence: Improving Cardiovascular Outcomes and the Role of Weight Loss Pharmacotherapy
|
May 06, 2024 |
|
Sandip Patel, MD - The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC
|
Mar 27, 2024 |
|
Taofeek K. Owonikoko, MD, PhD - Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic
|
Mar 26, 2024 |
|
Prof. Laurence Albiges, MD, PhD - Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors and Preparing for Innovative Delivery Approaches in the Clinic
|
Mar 14, 2024 |
|
Benjamin Levy, MD - Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer
|
Mar 14, 2024 |
|
Joshua Sabari, MD - Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon
|
Mar 14, 2024 |
|
Amy Shapiro, MD - A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations
|
Mar 14, 2024 |
|
Leonard B. Bacharier, MD - Episode 1: Is Your Patient’s Moderate to Severe Asthma Uncontrolled? Global Approaches to Next Steps
|
Mar 12, 2024 |
|
Klaus F. Rabe, MD, PhD, FERS - Episode 2: Which Patients Should Receive Targeted Biologic Therapy and When?
|
Mar 12, 2024 |
|
Arzu Yorgancioglu, MD - Episode 3: Uncontrolled Moderate to Severe Asthma in Pediatric and Adult Patients Around the World: Comparing Approaches to Treatment Selection
|
Mar 12, 2024 |
|
Leonard B. Bacharier, MD - Episode 4: What Are Our Most Significant Challenges in Treating Patients With Moderate to Severe Asthma and What Can We Learn From Each Other?
|
Mar 12, 2024 |
|
Nirmala Gonsalves, MD, AGAF, FACG - Timing Matters: Expert Insights on When to Use Targeted Biologic Therapy for Patients With Eosinophilic Esophagitis
|
Mar 11, 2024 |
|
Santosh L. Saraf, MD - Activating Better Care in SCD: Guidance on Novel PKR Agents, Other Innovative Therapies, and Modern Care Transitions
|
Mar 11, 2024 |
|
R. Scott Wright, MD - Targeting Elevated Cardiovascular Risk: Current Therapies and New Horizons in Hyperlipidemia Management
|
Feb 28, 2024 |
|
Jessica Donington, MD / Jonathan D. Spicer, MD, PhD, FRCSC - A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC
|
Feb 27, 2024 |
|
Brendon M. Stiles, MD - Building Multidisciplinary Partnerships to Facilitate Genomic Testing and Master the Integration of EGFR-Targeted Therapy in Resectable Stage I-III NSCLC
|
Feb 21, 2024 |
|
Joshua Sabari, MD - Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced NSCLC
|
Feb 09, 2024 |
|
Anjali Tiku Owens, MD - Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes
|
Feb 09, 2024 |
|
Vallerie V. McLaughlin, MD, Ioana R. Preston, MD - Changing Disease Course for Patients With Pulmonary Hypertension: Expert Insights on Improving Diagnosis and Novel Approaches to Treat the Underlying Causes
|
Feb 09, 2024 |
|
Vivian G. Oehler, MD - The Sequel to the Targeted Therapy Era in CML: Guidance on Integrating Novel Options Into Cohesive Sequential Care
|
Feb 08, 2024 |
|
Fernando J. Martinez, MD, MS - Cracking the Code in COPD: Understanding the Role of Type 2 Inflammation and Potential Clinical Implications of Targeted Treatment
|
Jan 31, 2024 |
|
Professor Benjamin Solomon, MBBS, PhD, FRACP, FAHMS - Adapting Our Strategies for Decision-Making in Testing and Treatment of RET-Altered Lung and Thyroid Cancers: A Personalized Learning Journey
|
Jan 31, 2024 |
|
Amy Shapiro, MD and Prof Pratima Chowdary, MD, FRCPATH- The ‘Clot’ Thickens in the Hemophilia Story: Clinical Perspectives on Enhancing Outcomes With Innovative Non-Factor Therapy
|
Jan 17, 2024 |
|
Jonathan Corren, MD / Mario Castro, MD - Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment
|
Jan 12, 2024 |
|
Jorge Plutzky, MD - At the Heart of Obesity: Evidence-Based Strategies for Managing Obesity to Reduce Cardiovascular Risks With Weight Loss Pharmacotherapy
|
Jan 12, 2024 |
|
Taofeek K. Owonikoko, MD, PhD - Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies
|
Jan 12, 2024 |
|
Benjamin Levy, MD - Under Pressure to Improve: How to Unlock the Power of Antibody–Drug Conjugates to Transform the Treatment of Lung Cancer
|
Dec 28, 2023 |
|
Matthew A. Gubens, MD, MS, FASCO - Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care
|
Dec 27, 2023 |
|
Roxana Mehran, MD / Jeffrey Weitz, MD, FRCPC, FRSC, FACP - Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care
|
Dec 12, 2023 |
|
Darren McGuire, MD, MHSc - Translating Data Into Practice: Examining the Impact of Weight Loss Pharmacotherapy on Cardiovascular Outcomes
|
Dec 12, 2023 |
|
Beth Sandy, MSN, CRNP, FAPO - Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care
|
Dec 06, 2023 |
|
Reynold A. Panettieri, Jr., MD - Expert Perspectives on Improving Early Recognition and Treatment of COPD With Inhalation Therapy
|
Nov 07, 2023 |
|
Ticiana Leal, MD - Optimizing the Care of Patients With SCLC in the Community Setting: How to Make the Most of the Latest Therapeutic Advances and Team-Based Best Practices
|
Nov 07, 2023 |
|
Hiddo J.L. Heerspink, PhD, PharmD / Prof. Dr. med Christoph Wanner - Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care
|
Nov 07, 2023 |
|
Truman J. Milling Jr., MD, FACEP - Reversal of Misfortune: Practical Insights for Managing Uncontrolled FXa-Inhibitor–Related Bleeding
|
Nov 07, 2023 |
|
Milind Desai, MD, MBA - Following the Evolution of Cardiac Myosin Inhibition: Remodeling Clinical Workflows to Realize the Greatest Benefit in oHCM and Beyond
|
Nov 07, 2023 |
|
Jessica Donington, MD - Unleashing the Potential of Perioperative Immunotherapy in Resectable NSCLC: Leveraging Science, Enhancing Collaboration, and Improving Outcomes With Neoadjuvant and/or Adjuvant Checkpoint Inhibition
|
Oct 31, 2023 |
|
Anjali Tiku Owens, MD - Removing Obstructions for Improved HCM Care: Leveling Up Diagnosis and Management in General Cardiology Practice
|
Oct 31, 2023 |
|
Michael R. Savona, MD / Andrew M. Brunner, MD - Command and Control MDS: New Science in MDS Management and Implications for Veteran-Centered Care
|
Oct 30, 2023 |
|
Stephen V. Liu, MD - A Bold Frontier: Shattering the Limits of Conventional Therapies and Reshaping the Future of Lung Cancer Treatment With TROP2-Targeting ADCs and Rational Combinations
|
Oct 23, 2023 |
|
Melissa L. Johnson, MD - Taking Aim With the Next Wave of Antibody–Drug Conjugates in NSCLC: Rational Strategies for Addressing the Unmet Needs of Diverse Patient Populations With TROP2- and HER3-Targeting Therapies and Other ADC-Based Regimens
|
Oct 06, 2023 |
|
Stacy E. Croteau, MD, MMS, Steven W. Pipe, MD - Expert Insights on Optimizing Patient Outcomes With Novel EHL FVIII Strategies in Hemophilia A
|
Sep 20, 2023 |
|
R. Scott Wright, MD - When Statins Strike Out: Using PCSK9-Targeting Strategies to Achieve Lipid Goals and Reduce Cardiovascular Risks in Patients With Hyperlipidemia
|
Aug 30, 2023 |
|
David J. Kuter, MD, DPhil / Cindy Neunert, MD, MSCS - New Rules for Overcoming ITP: Guidance on Later-Line Care, the Role of BTKi, and Improving Patient Outcomes
|
Aug 22, 2023 |
|
Alexander Drilon, MD - Selective, Potent, Different: How to Enhance Clinical Benefits With Next-Generation ROS1 and TRK Inhibition in Treatment-Naïve and Pretreated NSCLC and Other Tumors
|
Aug 11, 2023 |
|
Ruben A. Mesa, MD, FACP - Taking the Targeted Option for Myelofibrosis: Insights on Modern JAKi Platforms and Emerging Therapeutics
|
Aug 07, 2023 |
|
Stephen V. Liu, MD - Amplifying the ADC Advantage: How to Fulfill the Potential of Antibody–Drug Conjugates as the Next Frontier in Precision Lung Cancer Care
|
Jul 28, 2023 |
|
Pasi A. Jänne, MD, PhD - A Visual Exploration of New Targeted Therapies for EGFR Exon 20 Insertions in NSCLC: The Latest Evidence and Practical Guidance for Biomarker Testing and Individualized Treatment Selection and Sequencing
|
Jul 28, 2023 |
|
Steven W. Pipe, MD - Leading the Change in Hemophilia A: Guidance on Enhancing Prophylactic Care With Innovative EHL FVIII Products
|
Jul 28, 2023 |
|
Charles L. Daley, MD - Improving Time to Diagnosis of Non-Cystic Fibrosis Bronchiectasis: The Importance of the Radiologist in Fulfilling Unmet Needs of Patients
|
Jul 05, 2023 |
|
P. Barton Duell, MD - Straight From the Experts: Clinical Conversations on Modernizing Hyperlipidemia Management With PCSK9-Targeting Agents
|
Jul 05, 2023 |
|
Taofeek K. Owonikoko, MD, PhD - Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research
|
Jun 30, 2023 |
|
Clinical Pharmacology
|
Jun 30, 2023 |
|
Brett Elicker, MD - Taking a Look Ahead in Non–Cystic Fibrosis Bronchiectasis: Leveraging Early Diagnosis and Emerging Therapies to Improve Quality of Life
|
Jun 20, 2023 |
|
Patrick A. Flume, MD / Gwen A. Huitt, MD, MS - Improving the Patient Experience in Nontuberculous Mycobacterial Lung Disease: The Intersection of Early Diagnosis, Customized Therapy, and Adverse Event Management
|
Jun 01, 2023 |
|
Marianne Davies, DNP, ACNP, AOCNP, FAAN - Nurses at the Forefront of the Continuing Success Story of Immunotherapy in NSCLC: Best Practices for Guiding and Supporting Patients Through Treatment and Survivorship
|
Jun 01, 2023 |
|
Jonathan D. Spicer, MD, PhD, FRCSC - Neoadjuvant, Adjuvant, or Both: How to Solve the Puzzle of Perioperative Immunotherapy, Individualize Treatment Plans, and Improve Cure Rates in Resectable NSCLC
|
Jun 01, 2023 |
|
Catherine Shu, MD / Brendon M. Stiles, MD - Bringing Precision Lung Cancer Care to the Perioperative Space: How to Maximize the Impact of EGFR-Targeted Therapy in Resectable NSCLC
|
Jun 01, 2023 |
|
Natasha B. Leighl, MD, MMSc, FRCPC, FASCO - Refining Precision Decisions in NSCLC With Common and Less Common EGFR Mutations: Navigating Testing and Treatment Throughout the Disease Continuum
|
Apr 26, 2023 |
|
Neal K. Lakdawala, MD, Anjali Tiku Owens, MD - Loosening the Grip of Hypertrophic Cardiomyopathy: Updated Strategies for Timely Diagnosis and Disease-Modifying Treatment
|
Apr 06, 2023 |
|
Tricia Cottrell, MD, PhD, Lynette M. Sholl, MD - Gaining Confidence in Predicting and Assessing Response to Cancer Immunotherapies: Practical Strategies for Biomarker Testing and Pathologic Response Assessment
|
Apr 06, 2023 |
|
Sean Pokorney, MD, MBA - Episode 1. Looking for Trouble: The Role of Systematic Screening
|
Apr 05, 2023 |
|
Sean Pokorney, MD, MBA - Episode 2. Profiles in Comorbidity: Identifying Who Is at High Risk
|
Apr 05, 2023 |
|
Sean Pokorney, MD, MBA - Episode 3. Mending the Healthcare System: Reducing Disparities
|
Apr 05, 2023 |
|
Sean Pokorney, MD, MBA - Episode 4. The Fear Factor: Mitigating Patients’ Concerns About Anticoagulation
|
Apr 05, 2023 |
|
Sean Pokorney, MD, MBA - Episode 5. State-of-the-Art Treatment: Catching Up With Current Guidelines
|
Apr 05, 2023 |
|
Sean Pokorney, MD, MBA - Episode 6. Is That Realistic? What We’ve Learned About Anticoagulation Therapy From Real-World Studies
|
Apr 05, 2023 |
|
Sean Pokorney, MD, MBA - Episode 7. Marching to Their Own Rhythm: Using Consumer Wearables in AF Diagnosis and Treatment
|
Apr 05, 2023 |
|
Janis Taube, MD, MSc - Refining Best Practices in Cancer Immunotherapy Biomarker Testing and Pathologic Response Assessment
|
Mar 28, 2023 |
|
Jacob Sands, MD - Facilitating Progress in the Treatment of SCLC: How to Optimize the Use of Current Systemic Options and Accelerate the Clinical Transition of Investigational Approaches
|
Mar 28, 2023 |
|
Stephen V. Liu, MD - Perfecting Precision in Modern NSCLC Practice: Are You Optimally Integrating Biomarker-Driven Therapy?
|
Mar 28, 2023 |
|
Benjamin Levy, MD - Peer Pressure: How Well Do You Know Your ADCs? Answers to Key Questions About Antibody–Drug Conjugates in NSCLC
|
Mar 28, 2023 |
|
Prof. Mohamad Mohty, Christine N. Duncan, MD - New Rules for VOD/SOS: Modern Risk Assessment, Diagnostic Principles, and Innovative Treatment
|
Mar 14, 2023 |
|
Seth S. Martin, MD, MHS, FACC, FAHA, FASPC - Medicine in Motion: Smarter Approaches for Diagnosing HoFH
|
Mar 10, 2023 |
|
Professor Perry Elliott, MBBS, MD, FRCP, FESC, FACC - Medicine in Motion: Visual Guide to a New Generation in Care for Patients With Hypertrophic Cardiomyopathy
|
Mar 10, 2023 |
|
Seth S. Martin, MD, MHS, FACC, FAHA, FASPC - Medicine in Motion: Smart Approaches for Treating HoFH
|
Mar 03, 2023 |
|
Sanjay R. Bhagani, BSc (Hons), MB ChB, FRCP - Improving Outcomes for Hospitalized Patients with COVID-19: Expert Perspectives on Incorporating the Latest Guidelines and Evidence Into Clinical Practice
|
Mar 01, 2023 |
|
Jessica Donington, MD, Catherine Shu, MD - EGFR-Targeted Therapy for Early-Stage NSCLC: What Thoracic Surgeons Need to Know
|
Mar 01, 2023 |
|
Nasser Altorki, MD, Jonathan D. Spicer, MD, PhD, FRCSC - Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC: How to Modernize Best Practices Based on New Evidence and Better Multidisciplinary Alliances
|
Mar 01, 2023 |
|
Nikhil C. Munshi, MD - The Road to Remission in Multiple Myeloma: Expert Guidance on Using BCMA-Targeted Options to Enhance Clinical Outcomes
|
Feb 02, 2023 |
|
Nathan A. Pennell, MD, PhD, FASCO - Fine-Tuning Biomarker Testing to Identify and Target RET Fusions as Uncommon But Actionable Genomic Alterations in NSCLC
|
Feb 02, 2023 |
|
Grzegorz (Greg) Nowakowski, MD - Real-World, Real Innovation in DLBCL: Perspectives on Integrating Novel Antibody Platforms Into Patient Care
|
Jan 27, 2023 |
|
Jay B. Wish, MD - Novel Strategies for Managing Patients With CKD-Associated Anemia: What Do Health-System Pharmacists Need to Know About HIF-PH Inhibitors?
|
Jan 11, 2023 |
|
Guillermo Garcia-Manero, MD - The Future is Now in MDS: Integrating Innovative, Risk-Adapted Therapies Into Patient Management
|
Jan 11, 2023 |
|
Javid Moslehi, MD - Updating Our Cardio-Oncology Skills in the Cancer Immunotherapy Era: Team-Based Strategies for Risk Assessment, Diagnosis, and Management of Myocarditis and Other Cardiac Immune-Related Adverse Events
|
Jan 04, 2023 |
|
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 1: Why Are We Talking About VTE?
|
Dec 19, 2022 |
|
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 2: Tools for Unmasking VTE Quickly
|
Dec 19, 2022 |
|
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 3: Anticoagulation: When to Use It, With What, and for How Long?
|
Dec 19, 2022 |
|
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 4: How Can We Talk About VTE to Our Patients?
|
Dec 19, 2022 |
|
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 5: Knocking Down Barriers in Transitions of Care
|
Dec 19, 2022 |
|
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 6: What Is Real-World Evidence and How Is It Relevant and Important in VTE?
|
Dec 19, 2022 |
|
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 7: How Should VTE Be Managed in Patients With Obesity?
|
Dec 19, 2022 |
|
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 8: VTE in Cancer: How Concerning Is It and What Do We Do About It?
|
Dec 19, 2022 |
|
Javed Butler, MD, MPH, MBA - How I Think, How I Treat: Cardiology-Focused Perspectives on Using SGLT2 Inhibitors to Optimize Outcomes in Patients With Heart Failure
|
Dec 19, 2022 |
|
Caron Jacobson, MD - Unlocking the Benefits of CAR-T Therapy in Hematologic Malignancies: Latest Evidence and Practical Considerations for Delivering State-of-the-Art Care
|
Nov 30, 2022 |
|
Peter H. Jones, MD, MNLA, R. Scott Wright, MD - Personalizing the Management of Hyperlipidemia: Addressing Unmet Needs Among High-Risk Patients With Atherosclerotic Cardiovascular Disease With Novel Lipid-Lowering Therapies
|
Nov 30, 2022 |
|
Erik P. Sulman, MD, PhD - Harnessing Novel Synergies With Tumor Treating Fields: Insights on Improving Survival With Multimodal Care in Aggressive Tumors
|
Nov 22, 2022 |
|
Nasser Altorki, MD - Extending Survival and Setting Our Sights on Cure in Resectable NSCLC: Getting the Details of Perioperative Immunotherapy Right
|
Nov 17, 2022 |
|
R. Scott Wright, MD - Diagnosing and Treating Hyperlipidemia in Family Medicine: Exploring the Latest Clinical Evidence and the Role of Novel PCSK9-Targeting Therapies
|
Nov 17, 2022 |
|
Morie A. Gertz, MD - Don’t Miss the Rare When Diagnosing and Treating Autoimmune Hemolytic Anemia: Focus on CAD
|
Nov 14, 2022 |
|
Leonard B. Bacharier, MD / Monica Kraft, MD - Selecting Targeted Treatment for Pediatric and Adult Patients With Uncontrolled, Moderate to Severe Asthma
|
Nov 09, 2022 |
|
Natasha B. Leighl, MD, MMSc, FRCPC, FASCO - Refining Biomarker Testing and Targeted Treatment of NSCLC With Common and Uncommon EGFR Mutations
|
Nov 08, 2022 |
|
Milind Desai, MD, MBA - Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy?
|
Nov 08, 2022 |
|
Taofeek K. Owonikoko, MD, PhD - Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives on the State of the Science, Best Practices, Multidisciplinary Care, and Future Directions
|
Oct 28, 2022 |
|
Naval Daver, MD, Amir T. Fathi, MD - The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes
|
Oct 28, 2022 |
|
Brendon M. Stiles, MD - Precision Decisions in Multimodal Management of Early-Stage NSCLC: Integrating EGFR-Targeted Therapy in Perioperative Settings
|
Oct 28, 2022 |
|
Marina Chiara Garassino, MD - Are You Prepared for the New Wave of ADCs in NSCLC? Innovative Approaches and Practical Considerations in Targeting HER2, HER3, TROP2, and Other Alterations in Advanced Lung Cancer
|
Oct 28, 2022 |
|
Praneetha Thulasi, MD, Jonathan L. Kaufman, MD - The Eye-Deal Connection in Multiple Myeloma: Establishing Ophthalmology-Oncology Relationships to Overcome Ocular Toxicity
|
Oct 28, 2022 |
|
Nicole Lamanna, MD / Deborah M. Stephens, DO - Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices
|
Oct 28, 2022 |
|
Jivianne T. Lee, MD, FACS - Room to Breathe: Leveraging Biologic Agents and Multidisciplinary Care to Optimize Management in Chronic Rhinosinusitis With Nasal Polyps
|
Oct 07, 2022 |
|
Norman E. Lepor, MD, FACC, FAHA, FSCAI - Envisioning the Future of Hyperlipidemia Management: How Can We Leverage PCSK9-Targeting Therapies to Prevent Primary and Secondary Cardiovascular Events?
|
Oct 07, 2022 |
|
Alexander Drilon, MD - Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC
|
Sep 19, 2022 |
|
Wanda Phipatanakul, MD, MS - Controlling Moderate to Severe Asthma Across the Lifespan in an Ever-Evolving Treatment Landscape: How Much Do You Know?
|
Sep 02, 2022 |
|
Anjali Tiku Owens, MD - Going Beneath the Surface of Hypertrophic Cardiomyopathy: Understanding the Pathophysiology and Deploying New Strategies for Timely Diagnosis and Targeted Treatment
|
Sep 01, 2022 |
|
Julie V. Philley, MD; Kevin Winthrop, MD, MPH - Confronting the Challenges of Nontuberculous Mycobacterial Lung Disease: Expert Strategies for Reducing Diagnostic Delays and Improving Adherence to Guideline-Based Treatment
|
Aug 29, 2022 |
|
Professor Perry Elliott, MBBS, MD, FRCP, FESC, FACC - New Therapies, New Hope: Evolving Strategies for Improving Outcomes and Quality of Life in Patients With Hypertrophic Cardiomyopathy
|
Aug 25, 2022 |
|
Alexander Drilon, MD - Uncovering Gene Fusions and Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted Treatment
|
Aug 25, 2022 |
|
Robert Z. Orlowski, MD, PhD - Building Real-World Bridges Between Clinicians and Patients With Myeloma: Guidance on Innovative Antibody Options
|
Aug 11, 2022 |
|
Sagar Lonial, MD, FACP - Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy
|
Aug 09, 2022 |
|
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL
|
Aug 09, 2022 |
|
Jason Westin, MD, MS, FACP - Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR T-Cell Therapy in Community Practice
|
Aug 05, 2022 |
|
Anthony R. Mato, MD, MSCE - Rewriting the Treatment Script in CLL: Guidance on Integrating Modern Targeted and Next-Gen Options Into Patient Care
|
Aug 02, 2022 |
|
Prof. Dr. med. Stephan Stilgenbauer - New Rules for BTK Inhibitors in CLL: Benchmarks for Evidence-Based Treatment Selection, Sequencing, and Safety Management
|
Jul 25, 2022 |
|
Luke Maese, DO - Applying Therapeutic Innovations Against ALL: From Updated Evidence to Everyday Practice
|
Jul 22, 2022 |
|
David P. Carbone, MD, PhD - Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early Disease
|
Jul 20, 2022 |
|
Gail J. Roboz, MD - The Advantage of Innovation in AML: Guidance on Developing and Delivering Effective and Highly Personalized Care
|
Jul 20, 2022 |
|
Nina Shah, MD - The "Myelennial" Generation: Managing the Boom of Innovative Therapy to Transform Myeloma Care and Enhance Patient Outcomes
|
Jul 20, 2022 |
|
Zev A. Wainberg, MD - Targeting TIGIT to Extend Immunotherapy Benefits to More Cancer Patients: A Strategy to Amplify Immune Response and Enhance or Restore Antitumor Activity
|
Jul 08, 2022 |
|
Stuart S. Winter, MD - Adapting to Innovation in Pediatric ALL: Guidance on Optimizing Modern Therapy and the Role of Novel Asparaginase Compounds
|
Jul 08, 2022 |
|
James M. Foran, MD, FRCPC - Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT
|
Jul 06, 2022 |
|
Michael R. Bishop, MD - CAR-T Cell Therapy: Are You Up to the Challenge? New Evidence and Best Practices Driving Modern Cellular Therapies as a Standard of Care for Leukemia and Lymphoma
|
Jul 04, 2022 |
|
Stephen V. Liu, MD - Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer Care
|
Jun 29, 2022 |
|
Bruce R. Korf, MD, PhD - Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs
|
Jun 16, 2022 |
|
Nasser Altorki, MD - How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans to Improve Outcomes in Resectable NSCLC
|
Jun 14, 2022 |
|
Linda Ahn, MSN, ANP-BC, AOCNP - Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies
|
May 30, 2022 |
|
Prof. Solange Peters, MD, PhD - Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers
|
May 30, 2022 |
|
Jonathan Corren, MD - Airway Inflammation Isn’t the Only Problem: Shining a Light on the Role of Airway Hyper-Responsiveness in Severe Asthma
|
May 27, 2022 |
|
Kurt A. Schalper, MD, PhD - Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What’s New and What You Need to Know and Do
|
May 25, 2022 |
|
Joe R. Anderson, PharmD, PhC - Taking the Pulse of Undiagnosed Atrial Fibrillation: Pharmacists as a Lynchpin of Detection and Team-Based Care
|
May 23, 2022 |
|
Mark A. Socinski, MD - Expanding Options, Lingering Questions: How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC
|
May 23, 2022 |
|
Nina Shah, MD - Mapping the Therapeutic Odyssey in Multiple Myeloma: Interprofessional Guidance on Evidence-Based Treatment Selection and Sequencing
|
May 19, 2022 |
|
Jacob Sands, MD - Weighing the Evidence, Parsing the Practicalities: Integrating New Treatment Options Into the SCLC Treatment Arsenal to Improve Patient Outcomes in Oncology Practice
|
May 19, 2022 |
|
Michael E. Wechsler, MD - How I Think, How I Treat—Assessing, Managing, and Engaging Patients With Uncontrolled, Moderate to Severe Asthma: Comparing Approaches With Experts Around the World
|
May 13, 2022 |
|
Milind Desai, MD, MBA - New Evidence on Cardiac Myosin Inhibition in Hypertrophic Cardiomyopathy: Analysis From Washington, DC
|
May 05, 2022 |
|
Pasi A. Jänne, MD, PhD - Addressing Key Targets in Advanced NSCLC: Evaluating the Latest Evidence and Clinical Opportunities for HER2-, HER3-, and TROP2-Targeted Therapies
|
Apr 29, 2022 |
|
Anthony R. Mato, MD, MSCE - Solving the Challenge of Tumor Lysis Syndrome: Expert Insight and Guidance on a Challenging Oncologic Emergency
|
Apr 29, 2022 |
|
Geoffrey Barnes, MD, MSc - Primary Care Call to Action for VTE Management: Sharpening Skills in Recognition, Treatment, and Secondary Prevention
|
Apr 22, 2022 |
|
Gregory W. Albers, MD / S. Claiborne “Clay” Johnston, MD, PhD - Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Experts?
|
Apr 15, 2022 |
|
Nasser Altorki, MD / Jonathan D. Spicer, MD, PhD, FRCSC - Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes?
|
Apr 04, 2022 |
|
John B. Buse, MD, PhD - Complementary Actions All Around: Lowering Cardiometabolic Risks While Achieving Glycemic Targets With GLP-1 RAs
|
Apr 04, 2022 |
|
Purvi S. Parikh, MD, FACP, FACAAI / Cedric ""Jamie"" Rutland, MD - Taking It From the Top: Targeting a New Approach to Controlling Severe Asthma
|
Apr 01, 2022 |
|
Stephen V. Liu, MD - Visual Exploration of the Possibilities for Macrocyclic TKIs in Treatment-Naïve and Pretreated Fusion-Positive NSCLC and Other Tumors
|
Mar 31, 2022 |
|
Boris Sepesi, MD / Tina Cascone, MD, PhD - Bringing Precision Oncology to Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way: What Thoracic Surgeons Need to Know and Do
|
Mar 16, 2022 |
|
Paneez Khoury - Easing the Burden of Hypereosinophilic Syndrome: An Animated Exploration of the Role of Targeted Therapy to Improve Patient Outcomes
|
Feb 28, 2022 |
|
Grzegorz (Greg) Nowakowski, MD - Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy Into Patient Care
|
Feb 15, 2022 |
|
Lorinda Chung, MD, MS - Covering All the Bases in SSc-ILD Care: Expert Strategies for Diagnosis, Treatment, and Managing Comorbidities
|
Feb 01, 2022 |
|
Biree Andemariam, MD - The Evolution of Sickle Cell Disease: Current Advances and Future Possibilities
|
Feb 01, 2022 |
|
Neal K. Lakdawala, MD - Making New Strides in Hypertrophic Cardiomyopathy: The Latest Guidelines, Science, and Strategies for Early Diagnosis and Tailored Treatment
|
Jan 26, 2022 |
|
Nathan H. Fowler, MD - A Better Blend for Follicular Lymphoma: How Targeted, Epigenetic, and Immune Therapies Are Changing Patient Care
|
Jan 26, 2022 |
|
Stephen R. Broderick, MD, MPHS/Heather A. Wakelee, MD - Has Immunotherapy Brought Us to an Inflection Point in the Multimodal Management of Stage I-III NSCLC? Dissecting the Data and Instituting Multidisciplinary Alliances to Improve Outcomes in Early-Stage Disease
|
Jan 24, 2022 |
|
John C. Byrd, MD - Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety Management
|
Jan 20, 2022 |
|
Jennifer Wargo, MD, MMSc - Leveraging Neoadjuvant and Adjuvant Immunotherapy to Break Through the Outcomes Plateau, Prevent Recurrences, and Improve Curability in Early-Stage Cancers
|
Jan 11, 2022 |
|
David R. Jones, MD - Adjuvant EGFR-Targeted Therapy as a Game Changer: How to Implement New Standards of Care in Multimodal Management of Stage I-III EGFR-Mutated NSCLC
|
Dec 20, 2021 |
|
Javid Moslehi, MD - Improving the Detection and Management of Cardiac Immune-Related Adverse Events in Patients With Cancer Is a Must: Are You Prepared?
|
Dec 16, 2021 |
|
Lynette M. Sholl, MD - Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC: Refining and Expanding Best Practices in Advanced and Early-Stage Disease Settings
|
Dec 08, 2021 |
|
Jonathan W. Goldman, MD - Translating Science, Transforming Practice, and Making Headway Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next?
|
Nov 29, 2021 |
|
Andrew J. Wagner, MD, PhD - Overcoming the Challenges of Diverse TGCT Presentations: Diagnostic and Treatment Principles for the Multidisciplinary Team
|
Nov 09, 2021 |
|
Peter A. Kouides, MD - Advancing Treatment of von Willebrand Disease: A Visual Exploration on Personalizing Care With Current and Emerging Management Strategies
|
Oct 25, 2021 |
|
Daniel Jacoby, MD - Easing the Burden of Hypertrophic Cardiomyopathy: Progress in Understanding and Addressing Its Pathophysiology
|
Oct 19, 2021 |
|
Melissa L. Johnson, MD - Harnessing the Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC
|
Oct 19, 2021 |
|
Srdan Verstovsek, MD, PhD / Ruben A. Mesa, MD, FACP - Understanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on Molecular Biology, JAK Inhibitors, and Emerging Therapeutics
|
Oct 19, 2021 |
|
Anthony R. Mato, MD, MSCE - Interprofessional Perspectives on Safety Management With Targeted Therapy for B-Cell Malignancies
|
Oct 14, 2021 |
|
Sagar Lonial, MD, FACP - Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma Care
|
Oct 13, 2021 |
|
Ian Pavord, FMedSci - Across the Age Spectrum: Expert Insights on Emerging Uses of Targeted Therapy for the Treatment of Uncontrolled Moderate to Severe Asthma
|
Oct 12, 2021 |
|
Jared Weiss, MD - Raising the Bar for Patient Outcomes With Transcription Inhibition and Other New Options in the Treatment Arsenal for SCLC: Rationale, Mechanisms of Action, Latest Data, and Practicalities of Clinical Use in Oncology Practice
|
Oct 12, 2021 |
|
Anthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCL
|
Oct 11, 2021 |
|
Kenneth R. Cooke, MD - Collaborative Strategies for Managing VOD/SOS: Interprofessional Insights on Advances in Diagnosis, Severity Grading, and Treatment
|
Oct 11, 2021 |
|
Sanam Loghavi, MD - Secondary AML Through the Microscope: A Pathology-Informed Guide to Modern Diagnostic and Treatment Principles
|
Oct 06, 2021 |
|
Stephen V. Liu, MD - Maximizing the Potential of Immunotherapy in Multimodal Management of Unresectable Stage III NSCLC: Collaboration Is Crucial, Patient Selection Is Paramount, Close Monitoring Is Critical
|
Oct 06, 2021 |
|
Stephen V. Liu, MD - Tracking All the Targets in Genomically Altered NSCLC: Everything You Need to Know About Biomarker Testing and Treatment
|
Sep 29, 2021 |
|
Jamie E. Chaft, MD - Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung Cancer: Latest Data Informing Best Practices for Multimodal Management of Stage I-III NSCLC
|
Sep 29, 2021 |
|
Gail J. Roboz, MD - Clinical Consults on Modern AML Therapy: Where Precision Care Meets Potent Therapeutics
|
Sep 28, 2021 |
|
Ruben A. Mesa, MD, FACP - A Personalized Approach to Guide Risk-Adapted Treatment Decisions in Myelofibrosis: Applying the Latest Clinical Evidence on JAK Inhibitors and Novel Combination Therapies to Improve Patient Outcomes
|
Sep 10, 2021 |
|
Laura J. Zitella, MS, RN, ACNP-BC, AOCN - Taking the Fight to AML: Oncology Nurse Perspectives, Principles, and Practice in an Era of Innovative Therapies
|
Aug 31, 2021 |
|
Alok A. Khorana, MD, FACP, FASCO / Robert D. McBane, II, MD - Reducing the Global Burden of Cancer-Associated VTE: Applying Guideline-Concordant, Evidence-Based Care and Shared Decision-Making Strategies to Improve Patient Outcomes
|
Aug 17, 2021 |